Evidence map›Paper›PMID 35184425›Full record

ArticleYonsei medical journal2022

MEG3 LncRNA from Exosomes Released from Cancer-Associated Fibroblasts Enhances Cisplatin Chemoresistance in SCLC via a MiR-15a-5p/CCNE1 Axis.

Yulu Sun, Guijun Hao, Mengqi Zhuang, Huijuan Lv, Chunhong Liu, Keli Su

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Yonsei medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Current and future therapies for small cell lung carcinoma.Journal of hematology & oncology · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yulu Sun *Department of Oncology, The Fourth People's Hospital of Jinan, Jinan, China.ORCID https://orcid.org/0000-0002-9625-5782
Guijun Hao *Department of Oncology, The Fourth People's Hospital of Jinan, Jinan, China.ORCID https://orcid.org/0000-0003-1446-5952
Mengqi ZhuangDepartment of Oncology, The Fourth People's Hospital of Jinan, Jinan, China.ORCID https://orcid.org/0000-0001-5457-9386
Huijuan LvDepartment of Oncology, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China.ORCID https://orcid.org/0000-0001-8742-4348
Chunhong LiuDepartment of Oncology, The Fourth People's Hospital of Jinan, Jinan, China.ORCID https://orcid.org/0000-0003-0568-001X
Keli SuDepartment of Oncology, The Fourth People's Hospital of Jinan, Jinan, China. jnslsy20203106@163.com.ORCID https://orcid.org/0000-0003-4910-978X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLong non-coding RNAs (lncRNAs) may act as oncogenes in small-cell lung cancer (SCLC). Exosomes containing lncRNAs released from cancer-associated fibroblasts (CAF) accelerate tumorigenesis and confer chemoresistance. This study aimed to explore the action mechanism of the CAF-derived lncRNA maternally expressed gene 3 (MEG3) on cisplatin (DDP) chemoresistance and cell processes in SCLC. MATERIALS AND

methodsQuantitative real-time PCR was conducted to determine the expression levels of MEG3, miR-15a-5p, and CCNE1. Cell viability and metastasis were measured by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-h-tetrazolium bromide and invasion assays, respectively. A xenograft tumor model was developed to confirm the effect of MEG3 overexpression on SCLC progression in vivo. Relationships between miR-15a-5p and MEG3/CCNE1 were predicted using StarBase software and validated by dual luciferase reporter assay. Western blotting was used to determine protein levels. A co-culture model was established to explore the effects of exosomes on MEG3 expression in SCLC cell lines.

resultsMEG3 was overexpressed in SCLC tissues and cells. MEG3 silencing significantly repressed cell viability and metastasis in SCLC. High expression of MEG3 was observed in CAF-derived conditioned medium (CM) and exosomes, and promoted chemoresistance and cancer progression. Additionally, MEG3 was found to serve as a sponge of miR-15a-5p to mediate CCNE1 expression. Overexpression of miR-15a-5p and knockout of CCNE1 reversed the effects of MEG3 overexpression on cell viability and metastasis.

conclusionMEG3 lncRNA released from CAF-derived exosomes promotes DDP chemoresistance via regulation of a miR-15a-5p/CCNE1 axis. These findings may provide insight into SCLC therapy.

Indexed as

ExosomesMicroRNAsNeoplasmsRNA, Long NoncodingCisplatinCyclin EDrug Resistance, NeoplasmHumansOncogene ProteinsCCNE1 protein, humanCisplatinCyclin EMEG3 non-coding RNA, humanMicroRNAsOncogene ProteinsRNA, Long Noncodingcancer-associated fibroblastschemoresistanceexosomesMEG3Small-cell lung cancer

Identifiers

PMID35184425
PMCPMC8860932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.